Sign in

CIK 0000906709

  • Non-accelerated filer
  • Smaller reporting company

NEKTAR THERAPEUTICS

Sign in to watch
Ticker
NKTR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
943134940
Phone
+1 415-482-5300
Business address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
Former names
INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
  1. 4 Open-market sale Chief R&D Officer sold 1,157 shares at $54.28 ($62,802)
  2. 4 Open-market sale Chief Legal Officer sold 630 shares at $54.28 ($34,196)
  3. 4 Open-market sale President & CEO sold 2,207 shares at $54.28 ($119,796)
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Planned sale President & CEO sold 6,666 shares at an average $46.69 ($311,214)
  10. 4 Planned sale Chief R&D Officer sold 1,721 shares at an average $33.52 ($57,693)
  11. 4 Planned sale President & CEO sold 11,832 shares at an average $36.42 ($430,959)
  12. 4 Planned sale Chief R&D Officer sold 485 shares at $30.10 ($14,599)
  13. 4 Planned sale President & CEO sold 1,500 shares at $30.16 ($45,240)
  14. 4 Open-market sale Chief R&D Officer sold 725 shares at $26.59 ($19,278)
  15. 4 Open-market sale Chief Legal Officer sold 676 shares at $26.59 ($17,975)
  16. 4 Open-market sale President & CEO sold 1,573 shares at $26.59 ($41,826)
  17. 4 Open-market sale Chief R&D Officer sold 10,712 shares at $0.67 ($7,177)
  18. 4 Open-market sale Chief Legal Officer sold 9,996 shares at $0.67 ($6,697)
  19. 4 Open-market sale President & CEO sold 23,208 shares at $0.67 ($15,549)
  20. 4 Open-market sale Chief R&D Officer sold 10,300 shares at $1.01 ($10,403)

Page 2 of 49 · 968 filings